United States Patent 12,616,710: Scope, Claim-Chart Style Breakdown, and U.S. Patent Landscape for a Clindamycin Phosphate/Benzoyl Peroxide/Adapalene Topical Gel

Executive summary: U.S. Patent 12,616,710 claims a specific three-active topical gel composition for acne that combines (i) clindamycin phosphate at 1.2 wt%, (ii) benzoyl peroxide at 3.1 wt% with a particle-size/particulate form defined only by “plurality of benzoyl peroxide particles,” (iii) adapalene at 0.15 wt% with a “plurality of adapalene particles,” (iv) a defined polyhydric alcohol and a defined gelling agent from enumerated lists, (v) potassium hydroxide to achieve a defined pH range in a dependent claim, and (vi) stability at room temperature in a further dependent claim. The enforceable scope is primarily composition-and-formulation based in the U.S., with the most limiting features being the exact wt% targets, the particulate dispersion requirement (“uniformly dispersed”), and the constrained selection of excipients and pH/stability parameters.

What is the exact claim scope of U.S. Patent 12,616,710 for a clindamycin phosphate plus benzoyl peroxide plus adapalene topical gel?

Featured snippet answer: Independent claim 1 requires a topical gel with fixed concentrations (1.2 wt% clindamycin phosphate, 3.1 wt% benzoyl peroxide, 0.15 wt% adapalene), potassium hydroxide, and specific excipient families for the vehicle structure (a polyhydric alcohol selected from a named list; a gelling agent selected from a named list) with benzoyl peroxide and adapalene present as “plurality of particles” and uniformly dispersed.

Claim 1 structure and limiting elements

Claim 1 is a closed, multi-ingredient formulation claim built from several limiting blocks:

Drug actives and exact concentrations
- Clindamycin phosphate: 1.2 wt.%
- Benzoyl peroxide: 3.1 wt.%
  Defined as “a plurality of benzoyl peroxide particles.”
- Adapalene: 0.15 wt.%
  Defined as “a plurality of adapalene particles.”
Vehicle components with enumerated options
- Polyhydric alcohol: selected from:
  - propylene glycol
  - ethoxydiglycol
  - glycerol
  - combinations thereof
- Gelling agent: selected from a long enumerated list:
  - hydroxypropylcellulose
  - hydroxyethylcellulose
  - carboxyvinyl polymers
  - carboxyvinyl copolymers
  - polyacrylates
  - acrylate copolymers
  - acrylamide/sodium acryloyldimethyltaurate copolymers
  - methylcellulose
  - hydroxypropylmethylcellulose
  - xanthan gum
  - carrageenan gum
  - combinations thereof
Neutralizing/base component
- Potassium hydroxide present (amount not limited in claim 1).
Dispersion requirement
- “wherein the plurality of benzoyl peroxide particles and the plurality of adapalene particles are uniformly dispersed in the formulation.”

How courts typically read these limitations (practical legal consequence)

The claim is not an open Markush for the actives: the wt% numbers are exact targets.
It is a Markush-style constraint for the excipients: the polyhydric alcohol and gelling agent must come from the enumerated lists.
It adds a formulation science constraint via uniform dispersion of particulate benzoyl peroxide and particulate adapalene. This can become a key infringement battleground because “uniformly dispersed” is a functional/structural requirement that may be shown by analytical testing, microscopy, or validated distribution metrics.

How do dependent claims 2–4 narrow the formulation scope and affect infringement risk?

Claim 2: pH limitation

Claim 2 limits claim 1 by requiring:

Potassium hydroxide present in an amount to provide a pH of 5–6.

Impact: If an accused gel uses potassium hydroxide but targets pH outside 5–6 (or buffers to a different pH system), it can be an easy “non-infringement” lever. For infringement analysis, pH measurement conditions (time, temperature, sampling, stability phase) often matter because gels can drift.

Claim 3: room-temperature stability

Claim 3 requires:

Formulation stable at room temperature for at least six weeks.

Impact: This introduces a testability requirement and shifts the case toward stability data. It also increases design-around pathways: an accused product may match composition and pH but fail a six-week stability threshold, or it may use a different dispersion strategy that impacts peroxide/adapalene stability.

Claim 4: specific polyhydric alcohol

Claim 4 limits claim 1 by requiring:

Polyhydric alcohol is propylene glycol.

Impact: Claim 4 is narrower than claim 1. In litigation, it functions as an additional coverage “slice,” potentially capturing products that select propylene glycol. If a competitor uses glycerol or ethoxydiglycol, it would not meet claim 4.

What makes the claim “composition of matter” but with formulation performance features?

Core answer: U.S. 12,616,710 is a composition claim (it recites the ingredients, wt%, and defined excipient families), but it is strengthened by (i) physical form language (“plurality of particles”) and (ii) performance constraints (“uniformly dispersed,” pH 5–6, and six-week stability).

Particle language: “plurality” and “uniformly dispersed”

The particle language does two things:

It avoids being purely “dissolved” incorporation. “Plurality of particles” implies a particulate state, not fully molecularly dissolved actives.
It requires a distribution feature: benzoyl peroxide and adapalene particles must be uniformly dispersed.

Practical enforcement angle: If an accused product uses different polymorphs, solubilization systems, or surfactant-mediated dispersion that yields a different physical state, the defense may argue the claim’s “plurality” and dispersion requirements are not met.

What is the likely claim scope boundary around “same actives but different concentrations”?

Core answer: The independent claim fixes actives at 1.2 wt% clindamycin phosphate, 3.1 wt% benzoyl peroxide, and 0.15 wt% adapalene. Any meaningful deviation is a strong non-infringement argument.

Design-around logic

If a competitor adjusts concentrations outside the stated targets, it can avoid claim 1. Patent scope typically tracks the literal wt% numbers absent a doctrine of equivalents argument that courts may apply narrowly for percentage limits.
If a competitor retains exact concentrations but swaps excipient families (for polyhydric alcohol or gelling agent), it also avoids claim 1 because those components are constrained to enumerated lists.

How many separate formulation “routes” does claim 1 allow through the excipient lists?

Core answer: Claim 1 has a combinatorial set of allowed excipient choices:

Polyhydric alcohol: at least 3 single-member options plus combinations.
Gelling agent: 13 named members plus combinations.

Implication for infringement

Because the claim allows multiple excipient permutations, an accused product that stays within the allowed categories is more likely to land inside the claim. At the same time, the lists create clean exclusions for excipients not on the enumerated roster.

What would be the strongest infringement map for U.S. 12,616,710 (claim 1 to claim 4)?

Featured snippet answer: The tightest infringement case typically checks for: (1) clindamycin phosphate at 1.2 wt%, (2) benzoyl peroxide at 3.1 wt% as particulate material, (3) adapalene at 0.15 wt% as particulate material, (4) uniform dispersion of both particulate phases, (5) polyhydric alcohol from the listed set, (6) gelling agent from the listed set, (7) potassium hydroxide, (8) for dependent claims, pH 5–6 and stability of at least six weeks at room temperature, and (9) optionally propylene glycol for claim 4.

Claim elements checklist (litigation-ready)

Claim element	Requirement in 12,616,710	Typical proof in U.S. cases
Actives	Clindamycin phosphate 1.2 wt%; benzoyl peroxide 3.1 wt%; adapalene 0.15 wt%	Product label + lab assay
Physical form	“plurality of benzoyl peroxide particles” and “plurality of adapalene particles”	Microscopy, particle imaging, physical characterization
Dispersion	Both particle types “uniformly dispersed”	Distribution metrics, validated sampling, microscopy mapping
Polyhydric alcohol	Propylene glycol / ethoxydiglycol / glycerol / combos	Formulation composition analysis
Gelling agent	One of the listed gelling agents	Formulation and raw material identification
Base	Potassium hydroxide present	Ingredient ID and quantitative analysis
Dep. claim 2	pH 5–6	pH testing at relevant time/temperature
Dep. claim 3	stable at room temp ≥ 6 weeks	accelerated/real-time stability data
Dep. claim 4	polyhydric alcohol = propylene glycol	formulation verification

What does the claim suggest about the commercial product it targets in the U.S.?

Core answer: The claim reads like a topical acne combination gel using clindamycin phosphate, benzoyl peroxide, and adapalene together at fixed low-level adapalene and mid-level benzoyl peroxide, with a potassium hydroxide-adjusted pH and a specific gel polymer system.

Commercial significance of the excipient constraints: Many acne gels use carbomer-based matrices or different alcohol/solvent systems; the claim’s restricted gelling-agent list and base (potassium hydroxide) constrain the competitive universe.

How does the patent likely interact with Orange Book listings, paragraph IV, and generic entry risk for this category?

Core answer: Without Orange Book and litigation record details tied to the specific NDA/ANDA in question, the interaction with paragraph IV, settlement agreements, or generic entry risk cannot be accurately quantified. The claim set is formulation-specific and could be asserted against applicants selling substantially similar clindamycin phosphate/adapalene/benzoyl peroxide gels that match the constrained composition and particulate dispersion features.

Potential paragraph IV arguments (composition/formulation dependent)

In a certification challenge, a generic applicant would attempt to show non-infringement by changing:
- wt% targets
- excipient families
- particulate/dispersion characteristics
- pH range or stability profile
Patent holders would aim to show the generic formulation is within the enumerated lists and matches the uniform dispersion and particulate state.

What other U.S. patents commonly overlap for acne triple-combination topical gels, and where would 12,616,710 sit?

Core answer: For acne fixed-dose combinations, the patent estate often splits into:

active combination compositions,
formulation stability and particle engineering,
specific gelling vehicle systems,
pH/neutralization and shelf-life,
method-of-use or treatment regimen claims.

Based on the claim text provided, U.S. 12,616,710 is strongest on formulation composition with particulate uniform dispersion plus pH/stability dependent limits.

Where 12,616,710 likely provides incremental coverage

The “uniformly dispersed particulate” language suggests a differentiation from compositions that may rely on molecularly dissolved actives or non-uniform suspensions.
The potassium hydroxide and pH 5–6 dependent claim suggests a targeted compatibility window for peroxide and retinoid stability.

What would a competitor’s “design-around” package look like against claim 1?

Core answer: The most straightforward non-infringement strategies are:

move actives off the exact wt% numbers,
replace polyhydric alcohol or gelling agent with non-enumerated options,
avoid “plurality” particle form or eliminate uniform dispersion (using a different physical state or dispersion control),
avoid potassium hydroxide or change to another base to shift pH outside 5–6 (to defeat claim 2 and help claim 3 depending on stability).

Key Takeaways

Claim 1 is a constrained topical gel composition with exact wt% actives (1.2% clindamycin phosphate, 3.1% benzoyl peroxide, 0.15% adapalene), enumerated vehicle/excipient options, potassium hydroxide, and a key physical requirement: uniformly dispersed benzoyl peroxide and adapalene particles.
Claims 2 and 3 add measurable boundaries: pH 5–6 (claim 2) and room-temperature stability ≥ six weeks (claim 3). Claim 4 narrows further to propylene glycol as the polyhydric alcohol.
Most viable non-infringement levers are changes to exact wt% targets, excipient substitution outside the listed sets, and altering physical state/dispersion, pH range, or stability.

FAQs

Can a gel that matches wt% but uses a different base (not potassium hydroxide) infringe claim 1?
If benzoyl peroxide is dissolved rather than present as particles, does that avoid “plurality of benzoyl peroxide particles” in claim 1?
How is “uniformly dispersed” typically proven for topical gels in U.S. infringement disputes?
Does using propylene glycol instead of another listed polyhydric alcohol automatically satisfy claim 4 even if dispersion conditions differ?
What evidence best supports whether a formulation is “stable at room temperature for at least six weeks” under claim 3?

References

U.S. Patent 12,616,710 (claim text provided in prompt).

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Bausch	CABTREO	adapalene; benzoyl peroxide; clindamycin phosphate	GEL;TOPICAL	216632-001	Oct 20, 2023		RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial	Y				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2020322173	⤷ Start Trial
Canada	3149296	⤷ Start Trial
China	114126582	⤷ Start Trial
China	119837892	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 12,616,710

Which drugs does patent 12,616,710 protect, and when does it expire?

Summary for Patent: 12,616,710